Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients

NCT02434133
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Blood Draw/Data Collection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

Impact of Prebiotics in Ulcerative Colitis

NCT06495658
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Prebiotic
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

NCT04590508
View directory record Official record
Conditions
Crohn Disease
Interventions
Xanthohumol, Placebo
Drug · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease

NCT03266484
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Probiotic Mixture, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

NCT00454688
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
112
States / cities
Huntsville, Alabama • Pheonix, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

NCT05651542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Comprehensive Self-Management Intervention, Control
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

NCT03298022
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-168
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Newport Beach, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 1 Interventional

Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease

NCT01046773
View directory record Official record
Conditions
Crohn's Disease, Vitamin D Deficiency
Interventions
Cholecalciferol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome

NCT00108446
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
dextromethorphan, naloxone, fentanyl, lidocaine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

NCT03998488
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Fecal Microbiota Transplantation, Psyllium Husk Powder
Drug · Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

BOOM-IBD2 Pivotal Clinical Trial

NCT06571669
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Neuromodulation
Device
Lead sponsor
Boomerang Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Folsom, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Not applicable Interventional

Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography

NCT00591669
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Definity
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Plecanatide

NCT02706483
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
204
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 200 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

G-CSF to Treat Crohn's Disease

NCT00025805
View directory record Official record
Conditions
Crohn's Disease
Interventions
G-CSF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

NCT04543994
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Not yet recruiting Phase 4 Interventional

Combination CurQD and Vedolizumab in Ulcerative Colitis

NCT07665294
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CurQD, Placebo, Vedolizumab
Drug
Lead sponsor
Ryan C Ungaro
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome

NCT00955994
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
asimadoline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

NCT03759041
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
81
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

NCT03279081
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cx601, Placebo
Drug · Other
Lead sponsor
Tigenix S.A.U.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
68
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Broccoli Sprouts for Mild Ulcerative Colitis

NCT05507931
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Mild
Interventions
1 Serving of broccoli sprouts, 3 Servings of broccoli sprouts
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064454
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535 Tablets (drug)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Anal Dysplasia in Patients With Inflammatory Bowel Disease

NCT01653054
View directory record Official record
Conditions
IBD
Interventions
Anal Pap Smear, HPV DNA Testing
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Stony Brook, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262727
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 22, 2026, 5:25 AM EDT